General MedicationsINJECTIONGeneric
SUPPRELIN
HISTRELIN ACETATE
Standard Dose
EQ 0.2MG BASE/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview SUPPRELIN is listed in Drugs@FDA under application 019836 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient HISTRELIN ACETATE Form and strength INJECTABLE;INJECTION - EQ 0.2MG BASE/ML Sponsor SHIRE Submission history Latest submission status date: 1997-10-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview SUPPRELIN is listed in Drugs@FDA under application 019836 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient HISTRELIN ACETATE Form and strength INJECTABLE;INJECTION - EQ 0.2MG BASE/ML Sponsor SHIRE Submission history Latest submission status date: 1997-10-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.